Projekt
Cruz HBR
Abgeschlossen · 2020 bis 2022
Schneider Irene, Fink Karin, Weilenmann Daniel
Art
Klinische Forschung
Reichweite
Multizentrisch, KSSG als teilnehmendes Zentrum
Bereiche
Status
Abgeschlossen
Start
2020
Ende
2022
Finanzierungsart
Industrie
Studiendesign
Prospective, multi-center, open-label, single-arm registry designed to
enroll 1200 (800 non-High Bleeding Risk (non-HBR) and 400 HBR) allcomer patients with coronary artery disease in around 25 sites in 3
European countries (Switzerland, Germany & France).
Patients will receive at least one Supraflex Cruz™ sirolimus-eluting stent as per current practice and will be followed up for 12 months.
Kurzbeschreibung/Zielsetzung
Post-market registry to evaluate the safety and efficacy of the Supraflex Cruz™ sirolimus-eluting coronary stent system in the treatment of all-comer patients with coronary artery disease